Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1901 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Spain | 67 |
| 1902 | Apheresis | Allogeneic | Hemophagocytic Lymphohistiocytosis | Hematology | 2024 | Standard Therapy | United Kingdom | 48 |
| 1903 | Apheresis | Allogeneic | Non-Hodgkin’s lymphoma | Hematology | 2024 | Standard Therapy | NETHERLANDS | 61 |
| 1904 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 29 |
| 1905 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 1906 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Israel | 63 |
| 1907 | Apheresis | Allogeneic | ETP-Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 35 |
| 1908 | Apheresis | Allogeneic | Hodgkin lymphoma | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1909 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 23 |
| 1910 | Apheresis | Allogeneic | Fanconi Anemia | Hematology | 2024 | Standard Therapy | USA | 27 |
| 1911 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 69 |
| 1912 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 44 |
| 1913 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 49 |
| 1914 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 20 |
| 1915 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | France | 50 |
| 1916 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 74 |
| 1917 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Austria | 49 |
| 1918 | Apheresis | Allogeneic | Post-PV Myelofibrose | Hematology | 2024 | Standard Therapy | Germany | 59 |
| 1919 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 66 |
| 1920 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 1921 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 55 |
| 1922 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | France | 70 |
| 1923 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | France | 54 |
| 1924 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 68 |
| 1925 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 1926 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 31 |
| 1927 | Apheresis | Allogeneic | Other leukemia | Hematology | 2024 | Standard Therapy | Italy | 31 |
| 1928 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Sweden | 42 |
| 1929 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2024 | Standard Therapy | Germany | 43 |
| 1930 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2024 | Standard Therapy | Germany | 52 |
| 1931 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2024 | Standard Therapy | Germany | 64 |
| 1932 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 1933 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 70 |
| 1934 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 1935 | Apheresis | Allogeneic | Primary myelofibrosis | Hematology | 2024 | Standard Therapy | Germany | 55 |
| 1936 | Apheresis | Autologous | Amyloid Light-Chain Amyloidosis | Hematology | 2024 | Standard Therapy | Germany | 55 |
| 1937 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 1938 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 1939 | Apheresis | Autologous | Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 1940 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 1941 | Apheresis | Autologous | Angioimmunoblastic T-cell lymphoma | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 1942 | Apheresis | Allogeneic | Acute lymphoblastic leukemia | Hematology | 2024 | Standard Therapy | Germany | 19 |
| 1943 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 1944 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 1945 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Canada | 16 |
| 1946 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 1947 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 75 |
| 1948 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2024 | Standard Therapy | USA | 62 |
| 1949 | Apheresis | Allogeneic | Myelodysplastic Disorders | Hematology | 2024 | Standard Therapy | France | 66 |
| 1950 | Apheresis | Allogeneic | B-Cell Lymphoma | Hematology | 2024 | Standard Therapy | Canada | 70 |
| 1951 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Italy | 60 |
| 1952 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2024 | Standard Therapy | Poland | 57 |
| 1953 | Apheresis | Allogeneic | Diffuse large B-cell lymphoma | Hematology | 2024 | Standard Therapy | Poland | 17 |
| 1954 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 1955 | Apheresis | Allogeneic | Chronic lymphocytic leukemia | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 1956 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 1957 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 64 |
| 1958 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 76 |
| 1959 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 44 |
| 1960 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 1961 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | NETHERLANDS | 25 |
| 1962 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | USA | 42 |
| 1963 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | CROATIA | 66 |
| 1964 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 70 |
| 1965 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Switzerland | 68 |
| 1966 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukaemia | Hematology | 2024 | Standard Therapy | NETHERLANDS | 62 |
| 1967 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 58 |
| 1968 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 1969 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Belarus | 54 |
| 1970 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Spain | 9 |
| 1971 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 1972 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | France | 67 |
| 1973 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | France | 54 |
| 1974 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | South Africa | 54 |
| 1975 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 1976 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Sweden | 60 |
| 1977 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Spain | 67 |
| 1978 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 1979 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 53 |
| 1980 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 1981 | Apheresis | Autologous | Non-Hodgkin Lymphoma, rezidiv | Hematology | 2024 | Standard Therapy | Germany | 64 |
| 1982 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 57 |
| 1983 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 1984 | Apheresis | Allogeneic | Acute lymphoblastic leukemia | Hematology | 2024 | Standard Therapy | Germany | 50 |
| 1985 | Apheresis | Autologous | Multiple myeloma | Hematology | 2024 | Standard Therapy | Germany | 57 |
| 1986 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 70 |
| 1987 | Apheresis | Allogeneic | Multiple Organ Dysfunction Syndrome | Hematology | 2024 | Standard Therapy | Germany | 42 |
| 1988 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 32 |
| 1989 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 76 |
| 1990 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Italy | 63 |
| 1991 | Apheresis | Allogeneic | Early T-cell precursor Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Australia | 43 |
| 1992 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | USA | 72 |
| 1993 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 72 |
| 1994 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 1995 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 73 |
| 1996 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 1997 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Italy | 63 |
| 1998 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Czechia | 46 |
| 1999 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | France | 64 |
| 2000 | Apheresis | Allogeneic | Primary Immunodeficiencies | Hematology | 2024 | Standard Therapy | Russia | 7 |